IMRX · Insider Trading
Immuneering Corporation Class A Common Stock
Every open-market purchase and sale reported by IMRX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-17 | Andrew Gengos | Chief Financial Officer | A | +650,000 deriv. | — |
| 2026-06-24 | Benjamin J. Zeskind | PRESIDENT AND CEO | Buy | +2,400 | +$10.95K |
| 2026-06-16 | Brett Matthew Hall | CHIEF SCIENTIFIC OFFICER | Buy | +6,035 | +$25.05K |
| 2026-06-11 | Laurie Keating | Director | A | +33,350 deriv. | — |
| 2026-06-11 | Robert J Carpenter | Director | A | +33,350 deriv. | — |
| 2026-06-11 | Diana Hausman | Director | A | +33,350 deriv. | — |
| 2026-06-11 | Peter Feinberg | Director | A | +33,350 deriv. | — |
| 2026-06-11 | Thomas J. Schall | Director | A | +33,350 deriv. | — |
| 2026-03-17 | Leah R Neufeld | CHIEF PEOPLE OFFICER | A | +3,628 | +$15.57K |
| 2026-02-05 | Leah R Neufeld | CHIEF PEOPLE OFFICER | A | +140,000 deriv. | — |
| 2026-02-05 | Mallory Morales | SVP Finance, CAO | A | +140,000 deriv. | — |
| 2026-02-05 | Igor Matushansky | Chief Medical Officer | A | +140,000 deriv. | — |
| 2026-02-05 | Brett Matthew Hall | CHIEF SCIENTIFIC OFFICER | A | +344,000 deriv. | — |
| 2026-02-05 | Harold Eugene Brakewood | Chief Business Officer | A | +140,000 deriv. | — |
| 2026-02-05 | Michael Bookman | CHIEF LEGAL OFFICER, SECRETARY | A | +176,000 deriv. | — |
| 2026-02-05 | Benjamin J. Zeskind | PRESIDENT AND CEO | A | +688,000 deriv. | — |
| 2026-01-21 | Harold Eugene Brakewood | Chief Business Officer | Buy | +5,250 | +$24.99K |
| 2026-01-20 | Thomas J. Schall | Director | Buy | +21,645 | +$101.04K |
| 2026-01-16 | Brett Matthew Hall | CHIEF SCIENTIFIC OFFICER | Buy | +2,298 | +$10.50K |
| 2026-01-15 | Leah R Neufeld | CHIEF PEOPLE OFFICER | Buy | +2,626 | +$10.91K |
| 2026-01-14 | Peter Feinberg | Director | Buy | +20,000 | +$86.90K |
| 2026-01-02 | Laurie Keating | Director | A | +7,888 deriv. | — |
| 2026-01-02 | Peter Feinberg | Director | A | +7,888 deriv. | — |
| 2025-10-07 | Peter Feinberg | Director | Buy | +7,500 | +$50.02K |
| 2025-10-02 | Leah R Neufeld | CHIEF PEOPLE OFFICER | Buy | +800 | +$5.10K |
| 2025-10-02 | Mallory Morales | Chief Accounting Officer | Buy | +300 | +$1.92K |
| 2025-10-02 | Michael Bookman | CHIEF LEGAL OFFICER, SECRETARY | Buy | +1,020 | +$6.97K |
| 2025-10-01 | Peter Feinberg | Director | Buy | +7,500 | +$52.73K |
| 2025-09-30 | Peter Feinberg | Director | Buy | +5,000 | +$35.90K |
| 2025-09-17 | Leah R Neufeld | CHIEF PEOPLE OFFICER | A | +11,815 | +$16.87K |
| 2025-09-17 | Mallory Morales | Chief Accounting Officer | A | +14,497 | +$20.70K |
| 2025-09-17 | Brett Matthew Hall | CHIEF SCIENTIFIC OFFICER | A | +14,880 | +$21.25K |
| 2025-07-07 | Leah R Neufeld | CHIEF PEOPLE OFFICER | Buy | +700 | +$2.50K |
| 2025-07-07 | Diana Hausman | Director | Buy | +5,500 | +$19.86K |
| 2025-07-03 | Benjamin J. Zeskind | PRESIDENT AND CEO | Buy | +10,000 | +$34.88K |
| 2025-06-30 | Thomas J. Schall | Director | Buy | +9,500 | +$34.79K |
| 2025-06-24 | Brett Matthew Hall | CHIEF SCIENTIFIC OFFICER | Buy | +13,422 | +$34.62K |
| 2025-06-24 | Harold Eugene Brakewood | Chief Business Officer | Buy | +1,900 | +$4.80K |
| 2025-06-23 | Peter Feinberg | Director | Buy | +25,000 | +$63.19K |
| 2025-06-20 | Benjamin J. Zeskind | PRESIDENT AND CEO | Buy | +21,000 | +$50.14K |
| 2025-06-18 | Thomas J. Schall | Director | Buy | +40,485 | +$89.28K |
| 2025-06-16 | Diana Hausman | Director | A | +33,350 deriv. | — |
| 2025-06-16 | Robert J Carpenter | Director | A | +33,350 deriv. | — |
| 2025-06-16 | Laurie Keating | Director | A | +33,350 deriv. | — |
| 2025-06-16 | Ann E Berman | Director | A | +33,350 deriv. | — |
| 2025-06-16 | Peter Feinberg | Director | A | +33,350 deriv. | — |
| 2025-06-16 | Thomas J. Schall | Director | A | +33,350 deriv. | — |
| 2025-03-24 | Igor Matushansky | Chief Medical Officer | A | +118,000 deriv. | — |
| 2025-02-07 | Harold Eugene Brakewood | Chief Business Officer | A | +100,000 deriv. | — |
| 2025-02-07 | Brett Matthew Hall | CHIEF SCIENTIFIC OFFICER | A | +240,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Benjamin J. Zeskind | PRESIDENT AND CEO | 3,210,179 | $12.20M |
| Robert J Carpenter | Director | 823,839 | $3.13M |
| Brett Matthew Hall | CHIEF SCIENTIFIC OFFICER | 382,531 | $1.45M |
| Peter Feinberg | Director | 292,207 | $1.11M |
| Thomas J. Schall | Director | 74,530 | $283.31K |
| Ann E Berman | Director | 67,465 | $256.45K |
| Leah R Neufeld | CHIEF PEOPLE OFFICER | 29,598 | $112.51K |
| Mallory Morales | SVP Finance, CAO | 27,533 | $104.66K |
| Laurie Keating | Director | 14,000 | $53.22K |
| Harold Eugene Brakewood | Chief Business Officer | 11,050 | $42.00K |
| Diana Hausman | Director | 5,500 | $20.91K |
| Michael Bookman | CHIEF LEGAL OFFICER, SECRETARY | 4,870 | $18.51K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the IMRX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.